Literature DB >> 28979697

The ZDSD rat: a novel model of diabetic nephropathy.

Richard G Peterson1, Charles Van Jackson1, Karen M Zimmerman1.   

Abstract

The ZDSD rat is a new obese-diabetic rat model that expresses type 2 diabetes in the presence of an intact leptin pathway. During a long pre-diabetic state, the animals exhibit most of the features of metabolic syndrome including obesity, hyperlipidemia, hypertension, insulin resistance and decreased glucose disposal. The animals used in these studies were either allowed to become spontaneously diabetic at 16-30 weeks of age, or diabetes was induced with a diabetogenic diet. In the presence of either spontaneous or diet-induced diabetes, they develop progressive albuminuria as well as increases in other urinary markers of impaired renal function (kidney injury molecule-1 (KIM-1), β2-microglobulin, clusterin and cystatin C). Typical morphological changes of nephropathy, such as glomerular capillary basement membrane thickening and podocyte effacement, accompany these marker increases. Lisinopril (ACEi) treatment (30 mg/kg/day via the diet) dramatically reduced diabetes-induced albuminuria by 85%, independent of the duration of diabetes or the initial albumin excretion. These results position the ZDSD rat as a relevant model of diabetic nephropathy that can be treated with clinically effective compounds.

Entities:  

Keywords:  Diabetes; kidney; nephropathy; rat; renal

Year:  2017        PMID: 28979697      PMCID: PMC5622266     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  89 in total

1.  Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association.

Authors:  A C Schoolwerth; D A Sica; B J Ballermann; C S Wilcox
Journal:  Circulation       Date:  2001-10-16       Impact factor: 29.690

2.  Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-β-D-glucosaminidase.

Authors:  Vishal S Vaidya; Monika A Niewczas; Linda H Ficociello; Amanda C Johnson; Fitz B Collings; James H Warram; Andrzej S Krolewski; Joseph V Bonventre
Journal:  Kidney Int       Date:  2010-10-27       Impact factor: 10.612

Review 3.  Cystatin C: a step forward in assessing kidney function and cardiovascular risk.

Authors:  Johan Lassus; Veli-Pekka Harjola
Journal:  Heart Fail Rev       Date:  2012-03       Impact factor: 4.214

4.  Early renal injury induced by caffeine consumption in obese, diabetic ZSF1 rats.

Authors:  Stevan P Tofovic; Eman M Salah; Edwin K Jackson; Mona Melhem
Journal:  Ren Fail       Date:  2007       Impact factor: 2.606

Review 5.  Clusterin: physiologic and pathophysiologic considerations.

Authors:  M E Rosenberg; J Silkensen
Journal:  Int J Biochem Cell Biol       Date:  1995-07       Impact factor: 5.085

6.  Exogenous kallikrein protects against diabetic nephropathy.

Authors:  Wenjuan Liu; Yeping Yang; Yemei Liu; Xiaolan Lu; Shizhe Guo; Meng Wu; Meng Wang; Linling Yan; Qinghua Wang; Xiaolong Zhao; Xian Tong; Ji Hu; Yiming Li; Renming Hu; Robert C Stanton; Zhaoyun Zhang
Journal:  Kidney Int       Date:  2016-08-18       Impact factor: 10.612

7.  Renoprotective effects of olmesartan medoxomil on diabetic nephropathy in streptozotocin-induced diabetes in rats.

Authors:  Xiaofei Si; Peng Li; Yan Zhang; Yan Zhang; Wei Lv; Dong Qi
Journal:  Biomed Rep       Date:  2013-10-09

8.  Mitochondrial reactive oxygen species in the pathogenesis of early diabetic nephropathy.

Authors:  Takeshi Nishikawa; Michael Brownlee; Eiichi Araki
Journal:  J Diabetes Investig       Date:  2014-07-25       Impact factor: 4.232

Review 9.  Oxidative Stress in Diabetic Nephropathy with Early Chronic Kidney Disease.

Authors:  Alejandra Guillermina Miranda-Díaz; Leonardo Pazarín-Villaseñor; Francisco Gerardo Yanowsky-Escatell; Jorge Andrade-Sierra
Journal:  J Diabetes Res       Date:  2016-07-20       Impact factor: 4.011

10.  Effect of losartan and spironolactone on triglyceride-rich lipoproteins in diabetic nephropathy.

Authors:  Anand Srivastava; Beverley Adams-Huet; Gloria L Vega; Robert D Toto
Journal:  J Investig Med       Date:  2016-07-07       Impact factor: 2.895

View more
  5 in total

1.  Molecular changes in hepatic metabolism in ZDSD rats-A new polygenic rodent model of obesity, metabolic syndrome, and diabetes.

Authors:  Lu Han; Stefanie Bittner; Dachuan Dong; Yuan Cortez; Alex Bittner; Jackie Chan; Meenakshi Umar; Wen-Jun Shen; Richard G Peterson; Fredric B Kraemer; Salman Azhar
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2020-01-24       Impact factor: 5.187

2.  Blocking angiotensin 2 receptor attenuates diabetic nephropathy via mitigating ANGPTL2/TL4/NF-κB expression.

Authors:  Mona K Tawfik; Mohammed M Keshawy; Samy Makary
Journal:  Mol Biol Rep       Date:  2021-08-24       Impact factor: 2.316

Review 3.  Impact of Metabolic Surgery on Renal Injury in Pre-Clinical Models of Diabetic Kidney Disease.

Authors:  William P Martin; Carel W le Roux; Neil G Docherty
Journal:  Nephron       Date:  2020-12-02       Impact factor: 2.847

4.  Medications Activating Tubular Fatty Acid Oxidation Enhance the Protective Effects of Roux-en-Y Gastric Bypass Surgery in a Rat Model of Early Diabetic Kidney Disease.

Authors:  William P Martin; Yeong H D Chuah; Mahmoud Abdelaal; Anders Pedersen; Daniel Malmodin; Sanna Abrahamsson; Michaela Hutter; Catherine Godson; Eoin P Brennan; Lars Fändriks; Carel W le Roux; Neil G Docherty
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-26       Impact factor: 5.555

Review 5.  Zucker Diabetic-Sprague Dawley (ZDSD) rat: Type 2 diabetes translational research model.

Authors:  Andrea N Wang; Joselia Carlos; Graham M Fraser; John J McGuire
Journal:  Exp Physiol       Date:  2022-03-08       Impact factor: 2.858

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.